Union is strength: antiviral and anti-inflammatory drugs for COVID-19

• Published in: Drug discovery today Vol. 26; no. 1; pp. 229 - 239
• Main Authors: Naveja, Jose J., Madariaga-Mazón, Abraham, Flores-Murrieta, Francisco, Granados-Montiel, Julio, Maradiaga-Ceceña, Marco, Alaniz, Víctor Duarte, Maldonado-Rodriguez, Maricruz, García-Morales, Jazmín, Senosiain-Peláez, Juan Pablo, Martinez-Mayorga, Karina
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2021
• Subjects: Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - pharmacology; Antiviral Agents - administration & dosage; Antiviral Agents - pharmacology; COVID-19 - virology; COVID-19 Drug Treatment; Drug Repositioning; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Review
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2020.10.018

[Display omitted] •Treatment for moderately ill COVID-19 patients might arise from drug repurposing•RdRp, spike protein, and Mpro are relevant SARS-CoV-2 molecular targets.•Targeting human furin may contain viral infection and inflammation.•Molecular docking and clinical experience is useful for drug repurposing. Several clinical trials to treat Coronavirus 2019 (COVID-19) are in progress around the world. Some of them rely on clinical experience, whereas others include computational predictions. Here, we provide an overview of current efforts in the search for COVID-19 therapies, focusing on structural information of relevant targets. We elaborate on a robust pharmacological rationale for the repurposing of existing drugs, highlighting key advantages of dual therapies with antiviral and anti-inflammatory activity. Furthermore, we provide a consensus list of molecules that could undergo preliminary randomized clinical trials against COVID-19.